Immunosignaturing can detect products from molecular markers in brain cancer

Alexa K. Hughes, Zbigniew Cichacz, Adrienne Scheck, Stephen W. Coons, Stephen Johnston, Phillip Stafford

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors. Blood samples from patients undergoing craniotomies for therapeutically naïve brain tumors with diagnoses of astrocytoma (23 samples), Glioblastoma multiforme (22 samples), mixed oligodendroglioma/astrocytoma (16 samples), oligodendroglioma (18 samples), and 34 otherwise healthy controls were tested by immunosignature. Because samples were taken prior to adjuvant therapy, they are unlikely to be perturbed by non-cancer related affects. The immunosignaturing platform distinguished not only brain cancer from controls, but also pathologically important features about the tumor including type, grade, and the presence or absence of O6-methyl-guanine-DNA methyltransferase methylation promoter (MGMT), an important biomarker that predicts response to temozolomide in Glioblastoma multiformae patients.

Original languageEnglish (US)
Article numbere40201
JournalPloS one
Issue number7
StatePublished - Jul 16 2012

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Immunosignaturing can detect products from molecular markers in brain cancer'. Together they form a unique fingerprint.

Cite this